- Abbott’s adjusted earnings per share (EPS) for Q4 2025 matched expectations at $1.34, up from $1.19 in the previous year.
- Organic sales, excluding COVID-19 testing-related sales, increased by 10.1%, slightly below the previous year’s 11% growth and surpassing the estimate of 9.44%.
- The company’s net sales reached $10.97 billion, showing a 7.2% year-over-year increase, but fell short of the $11.01 billion estimate.
- Nutrition sales came in at $2.13 billion, up 4.5% from last year, but slightly missed the estimate of $2.16 billion.
- Diagnostics sales totaled $2.52 billion, a slight decline of 0.6% year-over-year, compared to an estimated $2.57 billion.
- COVID-19 testing-related sales were $176 million, down 34% quarter-over-quarter, and below the $192.2 million estimate.
- Established pharmaceuticals sales rose 3.8% year-over-year to $1.27 billion, but did not meet the $1.31 billion estimate.
- Medical devices sales significantly increased by 14% year-over-year to $5.05 billion, surpassing the estimate of $4.96 billion.
- Diabetes care sales grew by 20% year-over-year to $1.86 billion, exceeding the $1.83 billion estimate.
- Analyst recommendations include 20 buys, 9 holds, and 0 sells for Abbott.
Abbott Laboratories on Smartkarma
On Smartkarma, Abbott Laboratories has garnered positive analyst coverage from Baptista Research. In a report titled “Abbott Laboratories: A Tale Of Pipeline Productivity and Innovation! – Major Drivers,” the analysts highlight the company’s robust performance in the third quarter of 2024. With over 8% organic sales growth excluding COVID testing sales and adjusted earnings per share of $1.21, Abbott’s execution of its multifaceted strategy stands out. Particularly noteworthy is the 12% growth in the U.S. Pediatric Nutrition segment, driven by gains in the infant formula business.
In another report by Baptista Research, titled “Abbott Laboratories: Expanding Sensor Technology & Other Innovations! – Major Drivers,” the analysts emphasize the company’s strong overall performance in the second quarter of 2024. Abbott Laboratories exceeded analyst expectations with over 9% organic sales growth, excluding COVID testing sales, and a 16% sequential increase from the first quarter. This performance boost prompted an upward revision of guidance for the full year, with forecasted organic sales growth of 9.5% to 10% and adjusted earnings per share between $4.61 and $4.71.
A look at Abbott Laboratories Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Abbott Laboratories, a leading health care company, has garnered promising Smartkarma Smart Scores indicating a positive long-term outlook. With a solid momentum score of 4, Abbott shows strong potential for future growth and performance. Additionally, the company scores well in resilience, growth, and dividend categories, each with a score of 3. This suggests Abbott’s ability to weather economic uncertainties, maintain steady growth, and provide stable dividend returns which are key indicators of a well-rounded investment.
Abbott Laboratories‘ diverse line of healthcare products and global market presence further solidify its position for long-term success. While not scoring the highest in value, with a rating of 2, Abbott’s overall Smart Scores paint a picture of a company with strong fundamentals and growth potential, making it an attractive prospect for investors seeking stability and growth in the healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
